

CNS SPECTRUMS[®]

THE INTERNATIONAL JOURNAL OF NEUROPSYCHIATRIC MEDICINE

ORIGINAL RESEARCH

Serotonin Dysfunction in Pathological Gamblers: Increased Prolactin Response to Oral m-CPP Versus Placebo

S. Pallanti, S. Bernardi, L. Quercioli, C. DeCaria, and E. Hollander

The Shorter PROMIS Questionnaire and the Internet Addiction Scale in the Assessment of Multiple Addictions in a High-School Population: Prevalence and Related Disability

S. Pallanti, S. Bernardi, and L. Quercioli

Lamotrigine Combined with Divalproex or Lithium for Bipolar Disorder: A Case Series

J.R. Redmond, K.L. Jamison, and C.L. Bowden

REVIEW ARTICLES

The Neurobiology of Substance and Behavioral Addictions

J.E. Grant, J.A. Brewer, and M.N. Potenza


The Genetics of Gambling and Behavioral Addictions

D.S.S. Lobo and J.L. Kennedy

Impulsive-Compulsive Sexual Behavior

T.M. Mick and E. Hollander

New in the treatment of ADHD...



Think Daytrana™ –The Methylphenidate Patch


Important Safety Information

- Daytrana should not be used in patients with allergy to methylphenidate or patch components; marked anxiety, tension and agitation; glaucoma; tics, diagnosis or a family history of Tourette's syndrome; seizures; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).
- Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD. Physicians should take a careful patient history, including family history, and physical exam to assess the presence of cardiac disease. Patients who report symptoms of cardiac disease such as exertional chest pain and unexplained syncope should be promptly evaluated. Use with caution in patients whose underlying medical condition might be affected by increases in blood pressure or heart rate.
- New psychosis, mania, aggression, growth suppression, and visual disturbances have been associated with the use of stimulants. Use with caution in patients with a history of: psychosis; EEG abnormalities; bipolar disorder; depression. Growth and hematologic monitoring is advised during prolonged treatment. Patients should avoid applying external heat to the Daytrana patch. Skin irritation or contact sensitization may occur.
- Daytrana should be given cautiously to patients with a history of drug dependence and alcoholism. Chronic abuse can lead to marked tolerance and psychological dependence. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder.
- Common adverse events reported by patients who received Daytrana in clinical trials were decreased appetite, insomnia, nausea, vomiting, decreased weight, tics, affect lability, and anorexia, consistent with adverse events commonly associated with the use of methylphenidate.

References: 1. Daytrana [package insert]. Wayne, PA: Shire US Inc; 2006. 2. Wigal SB, Pierce DM, Dixon CM, McGough JJ. Pharmacokinetics of methylphenidate transdermal system in children with ADHD. Poster presented at: 18th Annual U.S. Psychiatric and Mental Health Congress; November 8, 2005; Las Vegas, Nev. 3. McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. *J Atten Disord.* 2006; 9:476-485. 4. Wigal S, McGough JJ, Abikoff H, et al. Behavioral effects of methylphenidate transdermal system in children with ADHD. Poster presented at: 52nd Annual Meeting of the American Academy of Child & Adolescent Psychology. October 20, 2005; Toronto, Ontario.

A new approach to treatment that has physicians, parents, patients, and teachers thinking along the same lines

- The next evolution in the delivery of methylphenidate¹
- Continuous delivery¹ for smooth levels of medication²
- Efficacy from the first time point measured (2 hours) through 12 hours, with a 9-hour wear time^{1,3,4}
- Wear-time flexibility—up to 9 hours—meets the changing daily needs of patients and parents¹
- Daytrana is indicated as an integral part of a comprehensive ADHD treatment program that may include other measures (psychological, educational, social). The efficacy of Daytrana was established in clinical trials in children aged 6 to 12 years¹



ADHD Treatment That Sticks³

Please see accompanying Brief Summary of Prescribing Information on adjacent page, including Boxed Warning.

Shire Daytrana™ is a trademark of Shire Pharmaceuticals Ireland Limited. www.Daytrana.com
Shire US Inc. ...your ADHD Support Company™ 1-800-828-2088 ©2006 Shire US Inc., Wayne, Pennsylvania 19087 D125 10/06

BRIEF SUMMARY: Consult the full prescribing information for complete product information.

Daytrana™ (methylphenidate transdermal system)

INDICATION AND USAGE

Attention Deficit Hyperactivity Disorder (ADHD): Daytrana™ (methylphenidate transdermal system) is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and is available in 10, 15, 20, and 30 mg dosing strengths. The efficacy of Daytrana™ was established in two controlled clinical trials in children with ADHD.

Speed of Onset of Central Nervous System Effects: Since the onset of this syndrome is unknown, there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV-TR characteristics.

Need for Comprehensive Treatment Program: Daytrana™ is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms of hyperactivity, impulsivity, and/or inattention, but whose overall functioning is normal. In addition to medication, educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms.

Long-Term Use: The effectiveness of Daytrana™ for long-term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. The physician who elects to use Daytrana™ for extended periods should periodically re-evaluate the long-term usefulness of Daytrana™ for the individual patient (see DOSAGE AND ADMINISTRATION).

CONTRAINDICATIONS

Agitation: Daytrana™ is contraindicated in patients with marked anxiety, tension, and agitation, since the drug may aggravate these symptoms.

Hypersensitivity to Methylphenidate: Daytrana™ is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product (polyester/ethylene vinyl acetate laminate film backing, acrylic adhesive, silicone adhesive, and fluoropolymer-coated polyester).

Glaucoma: Daytrana™ is contraindicated in patients with glaucoma.

Tics: Daytrana™ is contraindicated in patients with motor tics or with a family history or diagnosis of Tourette's syndrome (see ADVERSE REACTIONS).

Monoamine Oxidase Inhibitors: Daytrana™ is contraindicated during treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor (hypertensive crises may result).

WARNINGS

Serious Cardiovascular Events

Stroke and Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems

Children and Adolescents:

Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs.

Adults:

Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs.

Hypertension and Other Cardiovascular Conditions

Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm). In some individuals, however, these changes may be larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia.

Assessing Cardiovascular Status in Patients Being Treated With Stimulant Medications

Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including a family history of cardiovascular disease), physical examination, and medical exam to assess for the presence of cardiovascular disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should be referred to a prompt cardiac evaluation.

Contact Sensitization: Use of Daytrana™ may lead to contact sensitization. Daytrana™ should be discontinued if contact sensitization is suspected. Erythema is commonly seen with use of Daytrana™ and is not by itself an indication of sensitization. However, sensitization should be suspected if erythema is accompanied by evidence of a more intense local reaction (edema, papules, vesicles, or blisters) with an area of redness that spreads beyond the patch site. Diagnosis of allergic contact dermatitis should be corroborated by appropriate diagnostic testing.

Patients sensitized from use of Daytrana™, as evidenced by development of an allergic contact dermatitis, may develop systemic sensitization or other systemic reactions if methylphenidate-containing products are taken via other routes, e.g., orally. Manifestations of systemic sensitization may include a flare-up of previous dermatitis or prior positive patch-test sites, or generalized skin eruptions in previously unaffected skin. Other systemic reactions may include headache, fever, malaise, arthralgia, diarrhea, or vomiting.

Patients who develop contact sensitization to Daytrana™ and require oral treatment with methylphenidate should be initiated on oral methylphenidate under close medical supervision. It is possible that some patients sensitized to methylphenidate by exposure to Daytrana™ may not be able to tolerate methylphenidate in any form.

A study designed to provoke skin sensitization revealed a signal for Daytrana™ to be an irritant and also a contact sensitizer. This study involved an induction phase consisting of continuous exposure to the same skin site for 3 weeks, followed by a 2 week rest period, and then challenge/rechallenge. Under conditions of the study, Daytrana™ was more irritating than both the placebo patch control and the negative control (saline). Of 133 subjects who participated in the challenge phase of the sensitization study, at least 18 (13.5%) were confirmed to have been sensitized to Daytrana™ based on the results of the challenge and rechallenge phases of the study. The incidence of sensitization was 13.5%.

Using Daytrana™ as prescribed, alternating application sites on the hip, no cases of contact sensitization were reported. However, since patients were not specifically assessed for sensitization in the clinical effectiveness studies, it is unknown what the true incidence of sensitization is when Daytrana™ is used as directed.

Psychiatric Adverse Events

Pre-Existing Psychosis

Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.

Bipolar Illness

Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/maniac episode in such patients. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.

Emergence of New Psychotic or Manic Symptoms

Treatment-emergent manic symptoms (e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania) can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3,482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.

Aggression

Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behavior or hostility.

Long-Term Suppression of Growth: Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication-treated children over 36 months (to the ages of 10 to 13 years), suggests that children initially treated with methylphenidate may have a temporary slowing in growth rate (on average, a total of about 2 to 3 inches per year in height and 2 to 7% less growth in weight) for up to 1 year, without evidence of growth rebound during this period of development. Published data are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of growth. However, it is anticipated that they likely have this effect as well. Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.

Seizures: There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures and some prior history of EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.

Visual Disturbance: Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.

Use in Children Under Six Years of Age: Daytrana™ should not be used in children under six years of age, since safety and efficacy in this age group have not been established.

Drip Dependence

Daytrana™ should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parental abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow-up.

PRECAUTIONS

Potential for External Heat: All patients should be advised to avoid exposing the Daytrana™ application site to direct external heat sources, such as heating pads, electric blankets, heated beds, etc., while wearing the patch. There is a potential for temperature-dependent increases in methylphenidate release of greater than 2-fold from the patch.

Hematologic Monitoring: Periodic CBC, differential, and platelet counts are advised during prolonged therapy.

Information for Patients: Patients should be informed to apply Daytrana™ to a clean, dry site on the hip, which is not oily, damaged, or irritated. The site of application must be altered daily. The patch should not be applied to the waistline, or where light clothing may rub it.

Daytrana™ should be applied 2 hours before the desired effect. Daytrana™ should be removed approximately 9 hours after it is applied, although the effects from the patch will last for several more hours.

The parent or caregiver should be encouraged to use the administration chart included with each carton of Daytrana™ to monitor application and removal time, and method of disposal.

If there is an unacceptable duration of appetite loss or insomnia in the evening, taking the patch off earlier may be attempted before decreasing the patch size.

Skin redness or itching is common with Daytrana™, and small bumps on the skin may also occur in some patients. If any swelling, redness, or irritation occurs, the patch should not be worn and the patient should see the prescriber.

Drug Interactions: Daytrana™ should not be used in patients being treated (currently or within the preceding two weeks) with monoamine oxidase inhibitors (see CONTRAINDICATIONS-Monoamine Oxidase Inhibitors).

Because of a possible effect on blood pressure, Daytrana™ should be used cautiously with pressor agents.

III Rx Only

Methylphenidate may decrease the effectiveness of drugs used to treat hypertension.

Oral phenothiazines have shown decreased metabolism of coumarin anticoagulants, antidepressants (e.g., phenothiazine, imipramine, propantheline, desipramine) and selective serotonin reuptake inhibitors. Downward dose adjustments of these drugs may be required when given concomitantly with methylphenidate. It may be necessary to adjust the dosage and monitor plasma drug concentrations (or, in the case of coumarin, coagulation times), when initiating or discontinuing methylphenidate.

Serious adverse events have been reported in concomitant use of methylphenidate with clonidine, although no causality for the combination has been established. The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2-agonists has not been systematically evaluated.

Oral Contraceptives, Estrogen, and Impaired Fertility: Carcinogenicity studies of transdermal methylphenidate have not been performed. In a lifetime carcinogenicity study of oral methylphenidate carried out in BEC51 mice, methylphenidate caused an increase in hepatocellular adenomas and, in males only, an increase in hepatoblastomas, at a daily dose of approximately 60 mg/kg/day. Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant tumors. The mouse strain used is sensitive to the development of hepatic tumors and the significance of these results to humans is unknown.

Orally administered methylphenidate did not cause any increases in tumors in a lifetime carcinogenicity study carried out in female rats. The dose used was approximately 45 mg/kg/day.

In a 24-week oral carcinogenicity study in the transgenic mouse strain p53⁺, which is sensitive to genotoxic carcinogens, there was no evidence of carcinogenicity. In this study, male and female mice were fed diets containing the same concentration of methylphenidate as in the lifetime carcinogenicity study; the high-dose groups were exposed to 60 to 74 mg/kg/day of methylphenidate.

Methylphenidate was not mutagenic in the *in vitro* Ames reverse mutation assay or in the *in vitro* mouse lymphoma cell forward mutation assay, and was negative in *in vivo* in the mouse bone marrow micronucleus assay. Sister chromatid exchanges and chromosomal aberrations were increased, indicating a weak clastogenic response. In an *in vitro* assay in cultured Chinese hamster ovary cells, Daytrana™ did not impair fertility in male or female mice that were fed diets containing the drug in an 18-week Continuous Breeding study. The study was conducted at doses up to 160 mg/kg/day.

Pregnancy

Pregnancy Category C: Animal reproduction studies with transdermal methylphenidate have not been performed. In a study in which oral methylphenidate was given to pregnant rabbits during the period of organogenesis at doses up to 200 mg/kg/day, no teratogenic effects were seen. At the highest dose, there was a slight delay in fetal skeletal ossification. In a study in which oral methylphenidate was given to pregnant rabbits and lactation at doses up to 100 mg/kg/day, offspring weights and survival were decreased at 40 mg/kg/day and above; these doses caused some maternal toxicity.

At the highest dose, no effect on fetal survival was seen. A pre-implantation study in rabbits showed teratogenic effects of methylphenidate at an oral dose of 200 mg/kg/day. In a study in which oral methylphenidate was given to pregnant rats during the period of organogenesis at doses up to 100 mg/kg/day and above, these doses caused some maternal toxicity.

In a study in which oral methylphenidate was given to rats throughout pregnancy and lactation at doses up to 60 mg/kg/day, offspring weights and survival were decreased at 40 mg/kg/day and above; these doses caused some maternal toxicity.

At the highest dose, no effect on fetal survival was seen. A study in which oral methylphenidate was given to pregnant rats during the period of organogenesis at doses up to 100 mg/kg/day and above, these doses caused some maternal toxicity.

Mother Nursing Mothers: It is not known whether methylphenidate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised if Daytrana™ is administered to a nursing woman.

Pediatric Use: The safety and efficacy of Daytrana™ in children under 6 years old have not been established. Long-term effects of methylphenidate in children have not been well established (see WARNINGS).

Adolescents: In a study conducted in young rats, methylphenidate was administered orally at doses of up to 100 mg/kg/day, starting early in life. At the highest dose, there was a slight delay in skeletal ossification. In a study in which oral methylphenidate was given to adolescent rats, there was a slight delay in skeletal ossification.

Geriatric Use: In a study conducted in old rats, there was a slight delay in skeletal ossification. In a study in which oral methylphenidate was given to aged rats, there was a slight delay in skeletal ossification.

Adverse Reactions

The pre-marketing clinical development program for Daytrana™ included exposures in a total of 1,158 participants in clinical trials (758 pediatric patients) and 1,100 participants in open-label extension studies. Daytrana™ in patch sizes ranging from 10 mg to 30 mg was evaluated in 9 controlled clinical studies, 2 open-label clinical studies, and 4 clinical pharmacology studies. Adverse reactions were assessed by collecting adverse events data. Refer to the Full Prescribing Information for details of adverse event data collection.

Adverse Findings in Clinical Trials With Daytrana™

Events Associated With Discontinuation of Treatment: In a 7-week double-blind, parallel-group, placebo-controlled study in children and adolescents with ADHD, 1,100 participants treated with Daytrana™ discontinued due to adverse events, compared with 1,026 participants discontinued due to discontinuations among the patients treated with Daytrana™ were application site reactions, application site reaction, confusion, state, crying, IUGR, headache, irritability, infectious mononucleosis, and viral infection.

Adverse Events Occurring at an Incidence of 5% or More Among Patients Treated With Daytrana™: Table 1 enumerates the incidence of treatment-emergent adverse events reported in a 7-week double-blind, parallel-group, placebo-controlled study in children with ADHD conducted in the outpatient setting.

TABLE 1: Most Commonly Reported Treatment-Emergent Adverse Events ($\geq 5\%$ and $\geq 2x$ Placebo) in a 7-week Placebo-controlled Study

Adverse Event*	Daytrana™ (N = 98)	Placebo (N = 85)
Number of Subjects With ≥ 1 Adverse Event†	74 (76)	49 (58)
Nausea	12 (12)	2 (2)
Vomiting	10 (10)	4 (5)
Nasopharyngitis	5 (5)	2 (2)
Weight decreased	9 (9)	0 (0)
Anorexia	5 (5)	1 (1)
Decreased appetite	25 (26)	4 (5)
Affect labile	6 (6)	0 (0)
Insomnia	13 (13)	4 (5)
TIC	7 (7)	0 (0)
Nasal congestion	6 (6)	1 (1)

* Six subjects had affect labile, all judged as mild and described as increased anxiety, mood lability, emotional instability, emotional lability, and irritability.

† The majority of subjects in the pivotal phase III clinical efficacy study had minimal to definite erythema. This erythema generally caused no or minimal discomfort and did not usually interfere with therapy or result in discontinuation from treatment. If erythema, edema, and/or papules do not resolve or significantly improve within 24 hours, discontinuation of Daytrana™ should be evaluated.

Should be sought. Erythema is not in itself an indication of contact sensitization. However, sensitization should be considered if erythema is accompanied by edema, papules, vesicles, or other evidence of more intense local reactions.

Diagnosis of allergic contact dermatitis should be corroborated by appropriate diagnostic tests (see WARNINGS - Contact Sensitization).

Adverse Events With the Long-Term Use of Daytrana™: In a long-term open-label study of up to 40-month duration in 191 children with ADHD, the most frequently reported treatment-emergent adverse events in pediatric patients treated with Daytrana™ (12 hours/day) were:

• Headache, reports of Tourette's syndrome, tics; psychosis;

• Drowsiness, fatigue, sleepiness, daytime somnolence, daytime sleepiness, daytime drowsiness, daytime sleepiness, daytime somnolence;

• Headache, reports of hypertension, tics, psychoses, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

• Headache, daytime sleepiness, daytime somnolence, daytime sleepiness, daytime somnolence;

EDITORS

EDITOR EMERITUS

Jack M. Gorman, MD
Mount Sinai School of Medicine
New York, NY

EDITOR

Eric Hollander, MD
Mount Sinai School of Medicine
New York, NY

INTERNATIONAL EDITOR

Joseph Zohar, MD
Chaim Sheba Medical Center
Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS

EUROPE

Donatella Marazziti, MD
University of Pisa
Pisa, Italy

MID-ATLANTIC

Dan J. Stein, MD, PhD
University of Cape Town
Cape Town, South Africa

FAR EAST

Shigeto Yamawaki, MD, PhD
Hiroshima University School
of Medicine
Hiroshima, Japan

CONTRIBUTING WRITERS

Jon E. Grant, JD, MD, MPH
James L. Kennedy, MD, FRCPC
Thomas M. Mick, MD
Stefano Pallanti, MD, PhD
James R. Redmond, MD

COLUMNIST

Dan J. Stein, MD, PhD

MEDICAL REVIEWER

David L. Ginsberg, MD

CME COURSE DIRECTOR

Eric Hollander, MD

SUPPLEMENT EDITOR

Joseph Zohar, MD

EDITORIAL ADVISORY BOARD

NEUROLOGISTS

Mitchell F. Brin, MD
University of California, Irvine
Irvine, CA

Jeffrey L. Cummings, MD
University of California, Los Angeles
Los Angeles, CA

Jerome Engel, Jr., MD, PhD
University of California, Los Angeles
Los Angeles, CA

Mark S. George, MD
Medical University of South Carolina
Charleston, SC

Richard B. Lipton, MD
Albert Einstein College of Medicine
Bronx, NY

C. Warren Olanow, MD, FRCPC
Mount Sinai School of Medicine
New York, NY

Steven George Pavlakis, MD
Maimonides Medical Center
Brooklyn, NY

Stephen D. Silberstein, MD, FACP
Thomas Jefferson University
Philadelphia, PA

Michael Trimble, MD, FRCP, FRPsych
National Hospital for Neurology
and Neurosurgery
London, United Kingdom

PSYCHIATRISTS

Margaret Altemus, MD
Cornell University Medical College
New York, NY

Dennis S. Charney, MD
Mount Sinai School of Medicine
New York, NY

Dwight L. Evans, MD
University of Pennsylvania
Philadelphia, PA

Siegfried Kasper, MD
University of Vienna
Vienna, Austria

Martin B. Keller, MD
Brown Medical School
Providence, RI

Lorrin M. Koran, MD
Stanford University School of Medicine
Stanford, CA

Yves Lecrubier, MD

Hôpital de la Salpêtrière
Paris, France

Herbert Y. Meltzer, MD
Vanderbilt University Medical Center
Nashville, TN

Stuart A. Montgomery, MD
St. Mary's Hospital Medical School
London, United Kingdom

Charles B. Nemeroff, MD, PhD
Emory University School of Medicine
Atlanta, GA

Humberto Nicolini, MD, PhD
National Mexican Institute of Psychiatry
Mexico City, Mexico

Stefano Pallanti, MD, PhD
University of Florence
Florence, Italy

Katharine Phillips, MD
Brown Medical School
Providence, RI

Harold A. Pincus, MD
Western Psychiatric Institute & Clinic
RAND-University of Pittsburgh Health Institute,
Pittsburgh, PA

Scott L. Rauch, MD
Massachusetts General Hospital
Charlestown, MA

Alan F. Schatzberg, MD
Stanford University School of Medicine
Stanford, CA

Thomas E. Schlaepfer, MD
University of Bonn
Bonn, Germany

Stephen M. Stahl, MD, PhD
University of California, San Diego
La Jolla, CA

Norman Sussman, MD
New York University Medical School
New York, NY

Karen Dineen Wagner, MD, PhD
The University of Texas Medical Branch
Galveston, Texas

Herman G.M. Westenberg, MD
University Hospital Utrecht
Utrecht, The Netherlands

Stuart C. Yudofsky, MD
Baylor College of Medicine
Houston, TX

PUBLICATION STAFF

CEO & PUBLISHER

Darren L. Brodeur

ASSOCIATE PUBLISHER

Elizabeth Katz

VP, MANAGING EDITOR

Christopher Naccari

VP, SENIOR EDITOR

Deborah Hughes

SENIOR GLOBAL ACCOUNT DIRECTOR

Richard Ehrlich

SENIOR EDITOR—CNS SPECTRUMS

José Ralat

SENIOR ACQUISITIONS EDITOR

Lisa Arrington

ACQUISITIONS EDITOR

Virginia Jackson

ASSOCIATE EDITOR—ENDURING MATERIALS

Shelley Wong

ASSOCIATE EDITORS

Peter Cook—*Psychiatry Weekly*
Dena Croog—*Primary Psychiatry*

PUBLISHING SALES ASSOCIATE

Kimberly Schneider

MEDIA SALES REPRESENTATIVE

Jodi Malcom

ASSISTANT EDITOR

Rebecca Sussman

INTERNS

Carlos Perkins, Jr.
Stephanie Spano
Lonnie Stoltzfoos

ART DIRECTOR

Derek Oscarson

GRAPHIC DESIGNER

Michael J. Vodilko

CHIEF FINANCIAL OFFICER

John Spano

STAFF ACCOUNTANT

Diana Tan

INFORMATION TECHNOLOGY

Clint Bagwell Consulting

CORPORATION COUNSEL

Lawrence Ross, Esq.
Bressler, Amery, and Ross



Publishers of

PRIMARY PSYCHIATRY

The Leading Voice of Clinical Psychiatric Medicine

CNS SPECTRUMS

The International Journal of Neuropsychiatric Medicine

Psychiatry Weekly

The Leading News Service from Primary Psychiatry® and Psychiatry Weekly®

CNS Spectrums' 2005 ISI
Impact Factor Ranking 2.037

FACE LIFT COMPLETE!

Welcome to CNS Spectrums' New Web Portal...

www.cnsspectrums.com



*Click on the red PsychCast™ button at: www.cnsspectrums.com

After a six-month top-to-bottom redesign, *CNS Spectrums'* new Web portal is now better than ever — a one-stop source providing the following integrated services based on input from you... our readers:

- **Most-Read Articles** automatically tabulated
- **Quick Links** to Clinical Review Articles, Columns, News, & Educational Reviews
- **Keyword or Disease State-Based Article Search**
- **Integrated Customer Service Tools**
- **eLearning** via Enduring Materials & Monthly CME Section
- And a host of additional services and features... including simple hyperlink access to MBL's other CNS sources:
www.primarypsychiatry.com
and www.psychiatryweekly.com

To learn more, please visit: www.cnsspectrums.com or www.mblcommunications.com

PRIMARY PSYCHIATRY
The Leading Voice of Clinical Psychiatric Medicine

CNS SPECTRUMS
The International Journal of Neuropsychiatric Medicine

Psychiatry Weekly
The Leading News Service From Primary Psychiatry® and Physician's Weekly®

A Global Commitment to Advancing CNS Science, Clinical Practice, and Evidence-Based Medicine

EDITOR'S LETTER

- 903 Acting on Impulse: What's New About Impulse Control Disorders and Why Would We Consider Them Forms of Behavioral Addiction?**

Eric Hollander, MD, the Mount Sinai School of Medicine

INTRODUCTION

- 921 From Impulse-Control Disorders Toward Behavioral Addictions**

Stefano Pallanti, MD, PhD, Institute for Neuroscience at the Florence University of Medicine

ORIGINAL RESEARCH

- 915 Lamotrigine Combined with Divalproex or Lithium for Bipolar Disorder: A Case Series**

James R. Redmond, MD, University of Texas Health Science Center at San Antonio; Katrina L. Jamison, PharmD, GlaxoSmithKline; and Charles L. Bowden, MD, University of Texas Health Science Center at San Antonio

- 956 Serotonin Dysfunction in Pathological Gamblers: Increased Prolactin Response to Oral m-CPP Versus Placebo**

Stefano Pallanti, MD, PhD, Institute for Neuroscience at the Florence University of Medicine; Silvia Bernardi, MD, Università degli Studi di Firenze; Leonardo Quercioli, MD, Institute for Neuroscience at the Florence University of Medicine; Concetta DeCaria, PhD, the Mount Sinai School of Medicine; and Eric Hollander, MD, the Mount Sinai School of Medicine

- 966 The Shorter PROMIS Questionnaire and the Internet Addiction Scale in the Assessment of Multiple Addictions in a High-School Population: Prevalence and Related Disability**

Stefano Pallanti, MD, PhD, Institute for Neuroscience at the Florence University of Medicine; Silvia Bernardi, MD, Università degli Studi di Firenze; and Leonardo Quercioli, MD, Institute for Neuroscience at the Florence University of Medicine

REVIEW ARTICLES

- 924 The Neurobiology of Substance and Behavioral Addictions**

Jon E. Grant, JD, MD, MPH, University of Minnesota Medical School; Judson A. Brewer, MD, PhD, Yale University School of Medicine; and Marc N. Potenza MD, PhD, Yale University School of Medicine

- 931 The Genetics of Gambling and Behavioral Addictions**

Daniela S.S. Lobo, MD, PhD, Centre for Addiction and Mental Health at the University of Toronto; and James L. Kennedy, MD, FRCPC, Centre for Addiction and Mental Health at the University of Toronto


- 944 Impulsive-Compulsive Sexual Behavior**

Thomas M. Mick, MD, the Mount Sinai School of Medicine; and Eric Hollander, MD, the Mount Sinai School of Medicine

MISSION

CNS Spectrums' editorial mission is to address relevant neuropsychiatric topics, including the prevalence of comorbid diseases among patients, and original research and reports that emphasize the profound diagnostic and physiologic connections made within the neurologic and psychiatric fields. The journal's goal is to serve as a resource to psychiatrists and neurologists seeking to understand and treat disturbances of cognition, emotion, and behavior as a direct consequence of central nervous system disease, illness, or trauma.

This month's issue of CNS Spectrums, as well as a host of educational resources, enduring materials, and archived issues, is available at www.cnsspectrums.com.



Break the cycle

of unresolved depression with EFFEXOR XR^{1,2}

IMPORTANT TREATMENT CONSIDERATIONS

Suicidality in Children and Adolescents

Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of EFFEXOR XR or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. EFFEXOR XR is not approved for use in pediatric patients.

- EFFEXOR XR is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs).
- Adult and pediatric patients taking antidepressants can experience worsening of their depression and/or the emergence of suicidality. **Patients should be observed closely for clinical worsening and suicidality, especially at the beginning of drug therapy, or at the time of increases or decreases in dose.** Anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania have been reported and may represent precursors to emerging suicidality. Stopping or modifying therapy should be considered especially when symptoms are severe, abrupt in onset, or not part of presenting symptoms.

- The development of potentially life-threatening serotonin syndrome may occur when EFFEXOR XR is coadministered with other drugs that may affect the serotonergic neurotransmitter systems. Concomitant use of EFFEXOR XR with MAOIs is contraindicated. If concomitant use of EFFEXOR XR with an SSRI, SNRI, or a triptan is clinically warranted, careful observation of the patient is advised. Concomitant use of EFFEXOR XR with tryptophan supplements is not recommended.
- Treatment with venlafaxine is associated with sustained increases in blood pressure (BP) in some patients. Postmarketing cases of elevated BP requiring immediate treatment have been reported. Pre-existing hypertension should be controlled. Regular BP monitoring is recommended.
- Mydriasis has been reported in association with venlafaxine; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored.
- Abrupt discontinuation or dose reduction has been associated with discontinuation symptoms. Patients should be counseled on possible discontinuation symptoms and monitored while discontinuing the drug; the dose should be tapered gradually.

ONCE-DAILY
VENLAFAXINE HCl
EFFEXOR XR[®] EXTENDED RELEASE CAPSULES

The change they deserve.

Please see brief summary of Prescribing Information on adjacent pages.



BRIEF SUMMARY. See package insert for full prescribing information.

Suicidality in Children and Adolescents

Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of EFFEXOR XR or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. EFFEXOR XR is not approved for use in pediatric patients. (See Warnings and Precautions: Pediatric Use.)

Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with Major Depressive Disorder (MDD), obsessive-compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4,400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials.

CONTRAINDICATIONS: Hypersensitivity to venlafaxine hydrochloride or to any excipients in the formulation. Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs). **WARNINGS: Clinical Worsening and Suicide Risk—** Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. There has been a long-standing concern that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients. Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with MDD and other psychiatric disorders. It is unknown whether the suicidality risk in pediatric patients extends to longer-term use, i.e., beyond several months. It is also unknown whether the suicidality risk extends to adults. **All pediatric patients being treated with antidepressants for any indication should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months or a course of drug therapy, or at times of dose changes, either increases or decreases.** Adults with MDD or comorbid depression in the setting of other psychiatric illness being treated with antidepressants should be observed similarly for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania have been reported in adult and pediatric patients being treated with antidepressants for MDD and other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see PRECAUTIONS and DOSAGE AND ADMINISTRATION). Families and caregivers of pediatric patients being treated with antidepressants for MDD or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for Effexor XR should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose. Families and caregivers of adults being treated for depression should be similarly advised. **Screening Patients for Bipolar Disorder:** A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. Prior to initiating antidepressant treatment, patients with depressive symptoms should be screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. Effexor XR is not approved for use in treating bipolar depression. **Potential for Interaction with MAOIs—Adverse reactions, some serious, have been reported in patients who recently discontinued an MAOI and started on venlafaxine, or who recently discontinued venlafaxine prior to initiation of an MAOI.** These reactions included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, hyperthermia with features resembling neuroleptic malignant syndrome, seizures, and death. Effexor XR should not be used in combination with an MAOI, or within at least 14 days of discontinuing treatment with an MAOI. At least 7 days should be allowed after stopping venlafaxine before starting an MAOI. **Serotonin Syndrome—the development of potentially life-threatening serotonin syndrome may occur with Effexor XR treatment, particularly with (i) concomitant use of serotonergic drugs and (ii) with drugs that impair metabolism of serotonin (see CONTRAINDICATIONS—MAOIs).** If concomitant treatment of Effexor XR with an SSRI, SNRI, or a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of Effexor XR with serotonin precursors (such as triptophan supplements) is not recommended. **Sustained Hypertension—**Venlafaxine is associated with sustained increases in blood pressure (BP) in some patients. Postmarketing cases of elevated BP requiring immediate treatment have been reported. Pre-existing hypertension should be controlled. Regular monitoring of BP is recommended. For patients experiencing sustained increase in BP, consider either dose reduction or discontinuation. **Mydriasis:** Mydriasis has been reported; monitor patients with raised intraocular pressure or at risk of acute narrow-angle glaucoma (angle-closure glaucoma). **PRECAUTIONS: General—Discontinuation of Treatment with Effexor XR.** Abrupt discontinuation or dose reduction of venlafaxine at various doses is associated with new symptoms, the frequency of which increased with increased dose level and longer duration of treatment. Symptoms include agitation, anorexia, anxiety, confusion, coordination impaired, diarrhea, dizziness, dry mouth, dysphoric mood, emotional lability, fasciculation, fatigue, headaches, hypomania, insomnia, irritability, lethargy, nausea, nervousness, nightmares, seizures, sensory disturbances (e.g., paresthesias such as electric shock sensations), somnolence, sweating, tinnitus, tremor, vertigo, and vomiting. Monitor patients when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, consider resuming the previously prescribed dose. Subsequently, continue decreasing the dose at a more gradual rate. **Insomnia and Nervousness:** Treatment-emergent insomnia and nervousness have been reported. In Phase 3 trials, insomnia led to drug discontinuation in 1% of both depressed patients and Panic Disorder (PD) patients and in 3% of both Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder (SAD) patients. Nervousness led to drug discontinuation in 0.9% of depressed patients, in 2% of GAD patients, and in 0% of SAD and PD patients. **Changes in Weight: Adult Patients:** In short-term MDD trials, 7% of Effexor XR patients had ≥5% loss of body weight and 0.1% discontinued for weight loss. In 6-month GAD studies, 3% of Effexor XR patients had ≥7% loss of body weight and 0.3% discontinued for weight loss in 8-week studies. In 12-week SAD trials, 3% of Effexor XR patients had ≥7% loss of body weight and no patients discontinued for weight loss. In 12-week PD trials, 3% of Effexor XR patients had ≥7% loss of body weight, and no patients discontinued for weight loss. The safety and efficacy of venlafaxine in combination with weight loss agents, including phentermine, have not been established. Coadministration of Effexor XR and weight loss agents is not recommended. Effexor XR is not indicated for weight loss alone or in combination with other products. **Pediatric Patients:** Weight loss was seen in patients aged 6–17 receiving Effexor XR. More Effexor XR patients than placebo patients experienced weight loss of at least 3.5% in both MDD and GAD studies (18% of Effexor XR patients vs. 3.6% of placebo patients; $P<0.001$) and the SAD study (47% of Effexor XR patients vs. 14% of placebo patients; $P<0.001$). Weight loss was not limited to patients with treatment-emergent anorexia (decreased appetite). Children and adolescents in a 6-month MDD study had increases in weight less than expected based on data from age- and sex-matched peers. The difference between observed and expected weight gain was larger for children <12 years old than for adolescents ≥12 years old. **Changes in Height: Pediatric Patients:** In 8-week GAD studies, Effexor XR patients aged 6–17 grew an average of 0.3 cm ($n=122$), while placebo patients grew an average of 1.0 cm ($n=132$; $P=0.041$). This difference in height increase was most notable in patients <12. In 8-week MDD studies, Effexor XR patients grew an average of 0.8 cm ($n=146$), while placebo patients grew an average of 0.7 cm ($n=147$). During the 16-week, placebo-controlled SAD study, both the Effexor XR ($n=109$) and the placebo ($n=112$) patients grew an average of 1.0 cm. In the 6-month MDD study, children and adolescents had height increases less than expected based on data from age- and sex-matched peers. The difference between observed and expected growth rate was larger for children <12 years old than for adolescents ≥12 years old. **Changes in Appetite: Adult Patients:** Treatment-emergent anorexia was more commonly reported for Effexor XR (8%) than placebo (4%) patients in MDD

studies. The discontinuation rate for anorexia was 1.0% in MDD studies. Treatment-emergent anorexia was more commonly reported for Effexor XR (8%) than placebo (2%) patients in GAD studies. The discontinuation rate for anorexia was 0.9% for up to 8 weeks in GAD studies. Treatment-emergent anorexia was more commonly reported for Effexor XR (20%) than placebo (2%) patients in SAD studies. The discontinuation rate for anorexia was 0.4% for up to 12 weeks in SAD studies. Treatment-emergent anorexia was more commonly reported for Effexor XR (8%) than placebo (3%) patients in PD studies. The discontinuation rate for anorexia was 0.4% for Effexor XR patients in 12-week PD studies. **Pediatric Patients:** Decreased appetite was seen in pediatric patients receiving Effexor XR. In GAD and MDD trials, 10% of Effexor XR patients aged 6–17 for up to 8 weeks and 3% of placebo patients had treatment-emergent anorexia. None of the patients receiving Effexor XR discontinued for anorexia or weight loss. In the placebo-controlled trial for SAD, 22% and 3% of patients aged 6–17 treated for up to 16 weeks with Effexor XR and placebo, respectively, reported treatment-emergent anorexia (decreased appetite). The discontinuation rates for anorexia were 0.7% and 0.0% for patients receiving Effexor XR and placebo, respectively. The discontinuation rates for weight loss were 0.7% for patients receiving either Effexor XR or placebo. **Activation of Mania/Hypomania:** Mania or hypomania has occurred during short-term depression and PD studies. As with all drugs effective in the treatment of MDD, Effexor XR should be used cautiously in patients with a history of mania. **Hypotension/Hypotremia and/or the syndrome of inappropriate antidiuretic hormone secretion (SIADH):** may occur with venlafaxine. Consider this in patients who are volume-depleted, elderly, or taking diuretics. **Seizures:** In all premarketing depression trials with Effexor, seizures were reported in 0.3% of venlafaxine patients. Use cautiously in patients with a history of seizures. Discontinue in any patient who develops seizures. **Abnormal Bleeding:** Abnormal bleeding (most commonly ecchymosis) has been reported. **Serum Cholesterol/Elevation:** Clinically relevant increases in serum cholesterol were seen in 5.3% of venlafaxine patients and 0.0% of placebo patients treated for at least 3 months in trials. Consider measurement of serum cholesterol levels during long-term treatment. **Use in Patients With Concomitant Illness:** Use Effexor XR cautiously in patients with diseases or conditions that could affect hemodynamic responses or metabolism. Venlafaxine has not been evaluated in patients with recent history of MI or unstable heart disease. Increases in QT interval (QTc) have been reported in clinical studies. Exercise caution in patients whose underlying medical conditions might be compromised by increases in heart rate. In patients with renal impairment or cirrhosis of the liver, the clearances of venlafaxine and its active metabolites were decreased, prolonging the elimination half-lives. A lower dose may be necessary; use with caution in such patients. **Information for Patients—**Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Effexor XR and should counsel them in its appropriate use. A patient Medication Guide About Using Antidepressants in Children and Teenagers is available for Effexor XR. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is available at www.effexorxr.com or in the approved prescribing information. Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Effexor XR. **Clinical Worsening and Suicide Risk:** Patients, their families, and their caregivers should be encouraged to be alert to the emergence of symptoms listed in **WARNINGS: Clinical Worsening and Suicide Risk,** especially those seen early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication. Caution patients 1) about operating hazardous machinery, including automobiles, until they are reasonably sure that venlafaxine does not adversely affect their abilities; 2) to avoid alcohol while taking Effexor XR; and 3) about the risk of serotonin syndrome with the concomitant use of Effexor XR and triptans, tramadol, tryptophan supplements, or other serotonergic agents. Patients should be advised to notify their physician 1) if they become pregnant or intend to become pregnant during therapy, or if they are nursing; 2) about other prescription or over-the-counter drugs, including herbal preparations and nutritional supplements they are taking or plan to take; 3) if they develop a rash, hives, or related allergic phenomena; or 4) if they have a history of glaucoma or increased intracranial pressure. **Laboratory Tests—**No specific laboratory tests are recommended. **Drug Interactions—Alcohol:** A single dose of ethanol had no effect on the pharmacokinetics (PK) of venlafaxine or D-desmethylvenlafaxine (ODV). Venlafaxine did not exaggerate the psychomotor and psychometric effects induced by ethanol. **Cimetidine:** Use caution when administering venlafaxine with cimetidine to patients with pre-existing hypertension or hepatic dysfunction, and the elderly. **Diazepam:** A single dose of diazepam did not appear to affect the PK of either venlafaxine or ODV. Venlafaxine did not have any effect on the PK of diazepam or its active metabolite, desmethylzolazepam, or affect the psychomotor and psychometric effects induced by diazepam. **Haloperidol:** Venlafaxine decreased total oral-dose clearance of haloperidol, resulting in a 70% increase in haloperidol AUC. The haloperidol C_{max} increased 88%, but the haloperidol elimination half-life was unchanged. **Lithium:** A single dose of lithium did not appear to affect the PK of either venlafaxine or ODV. Venlafaxine had no effect on the PK of lithium. **Drugs Highly Bound to Plasma Proteins:** Venlafaxine is not highly bound to plasma proteins; coadministration of Effexor XR with a highly protein-bound drug should not cause increased free concentrations of the other drug. **Drugs That Inhibit Cytochrome P450 Isozymes:** CYP2D6 Inhibitors: Venlafaxine is metabolized to its active metabolite, ODV, by CYP2D6. Drugs inhibiting this isozyme have the potential to increase plasma concentrations of venlafaxine and decrease concentrations of ODV. No dosage adjustment is required when venlafaxine is coadministered with a CYP2D6 inhibitor. Concomitant use of venlafaxine with drug treatments that potentially inhibit both CYP2D6 and CYP3A4, the primary metabolizing enzymes for venlafaxine, has not been studied. Use caution if therapy includes venlafaxine and any agents (any) that produces simultaneous inhibition of these two enzyme systems. **Drugs Metabolized by Cytochrome P450 Isozymes:** Venlafaxine is a relatively weak inhibitor of CYP2D6. Venlafaxine did not inhibit CYP1A2 and CYP3A4, CYP2C9 (in vitro), or CYP2C19. **Imatinib:** Venlafaxine did not affect the PK of imatinib and 2-OH-imatinib. However, desipramine AUC, C_{max} , and C_{last} increased by ~35% in the presence of venlafaxine. The 2-OH-desipramine AUCs increased by 2.5–4.5 fold. Imatinib did not affect the PK of venlafaxine and ODV. **Risperidone:** Venlafaxine slightly inhibited the CYP2D6-mediated metabolism of risperidone to its active metabolite, 9-hydroxyrisperidone, resulting in a ~32% increase in risperidone AUC. Venlafaxine coadministration did not significantly alter the PK profile of the total active moiety (risperidone plus 9-hydroxyrisperidone). **CYP3A4:** Venlafaxine did not inhibit CYP3A4 in vitro and in vivo. **Indinavir:** In a study of 9 healthy volunteers, venlafaxine administration resulted in a 28% decrease in the AUC of a single dose of indinavir and a 36% decrease in indinavir C_{max} . Indinavir did not affect the PK of venlafaxine and ODV. **CYP1A2:** Venlafaxine did not inhibit CYP1A2 in vitro and in vivo. **CYP2C9:** Venlafaxine did not inhibit CYP2C9 in vitro. In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the PK of a single 550-mg dose of tolbutamide or the CYP2C9-mediated formation of 4-hydroxy-tolbutamide. **CYP2C19:** Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see *Diazepam above*). **MAOIs:** See CONTRAINDICATIONS and WARNINGS. **CNS-Active Drugs:** Use caution with concomitant use of venlafaxine and other CNS-active drugs. **Serotonergic Drugs and Triptans (see WARNINGS: Serotonin Syndrome):** Based on the mechanism of action of Effexor XR and the potential for serotonin syndrome, caution is advised when Effexor XR is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. John's wort. If concomitant treatment of Effexor XR with these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of Effexor XR with these drugs is not recommended. **Electroconvulsive Therapy (ECT):** There are no clinical data establishing the benefit of ECT combined with Effexor XR treatment. **Carcinogenesis, Mutagenesis, Impairment of Fertility—Carcinogenesis:** There was no increase in tumors in mice and rats given up to 1.7 times the maximum recommended human dose (MRHD) on a mg/m² basis. **Mutagenesis:** Venlafaxine and ODV were not mutagenic in the Ames reverse mutation assay in *Salmonella* bacteria or the CHO/IGPRT mammalian cell forward gene mutation assay. Venlafaxine was not clastogenic in several assays. ODV elicited a clastogenic response in the *in vivo* chromosomal aberration assay in rat bone marrow. **Impairment of Fertility:** No effects on reproduction or fertility in rats were noted at oral doses of up to 2 times the MRHD on a mg/m² basis. **Pregnancy—Teratogenic Effects—Pregnancy Category C:** Reproduction studies in rats given 2.5 times, and rabbits given 4 times the MRHD (mg/m² basis) revealed no malformations in offspring. However, in rats given 2.5 times the MRHD, there was a decrease in pup weight, an increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation when dosing began during pregnancy and continued until weaning. There are no adequate and well-controlled studies in pregnant women; use Effexor XR during pregnancy only if clearly needed. **Nonteratogenic Effects:** Neonates exposed to Effexor XR late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Complications can arise immediately upon delivery. Reports include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertension, hyperreflexia, tremor, jitteriness, irritability, and constant crying. This is consistent with a direct toxic effect of SNRIs or a drug discontinuation syndrome. In some cases, it is consistent with serotonin syndrome. When treating a pregnant woman with Effexor XR during the third trimester, carefully consider the potential risks and benefits of treatment and consider tapering Effexor XR in the third trimester. **Labor, Delivery, Nursing—**The effect on labor and delivery in humans is unknown. Venlafaxine and ODV have been reported to be excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Effexor XR, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. **Pediatric Use—Safety and Effectiveness in the Pediatric Population:** No studies have adequately assessed the impact of Effexor XR on growth, development, and maturation of children and adolescents. Studies suggest Effexor XR may adversely affect weight and height (see PRECAUTIONS—General, Changes in Height and Changes in Weight). Should the decision be made to treat a pediatric patient with Effexor XR, regular monitoring of weight and height is recommended during treatment, particularly if long term. The safety of Effexor XR for pediatric patients has not been assessed for chronic treatment >6 months. In studies in patients aged 6–17, blood pressure and cholesterol increases considered to be clinically relevant

were similar to that observed in adult patients. The precautions for adults apply to pediatric patients. **Geriatric Use**—No overall differences in effectiveness or safety were observed between geriatric and younger patients. Greater sensitivity of some older individuals cannot be ruled out. Hypotension and SIADH have been reported, usually in the elderly. **ADVERSE REACTIONS: Associated with Discontinuation of Treatment**—The most common events leading to discontinuation in MDD, GAD, SAD, and PD trials included nausea, anorexia, anxiety, impotence, dry mouth, dizziness, insomnia, somnolence, hypertension, diarrhea, paresthesia, tremor, abnormal (mostly blurred) vision, abnormal (mostly delayed) ejaculation, asthenia, vomiting, nervousness, headache, vasodilation, thinking abnormal, decreased libido, and sweating. **Commonly Observed Adverse Events in Controlled Clinical Trials for MDD, GAD, SAD, and PD**—**Body as a Whole:** asthenia, headache, flu syndrome, accidental injury, abdominal pain. **Cardiovascular:** vasodilatation, hypertension, palpitation. **Digestive:** nausea, constipation, anorexia, vomiting, flatulence, diarrhea, eructation. **Metabolic/Nutritional:** weight loss. **Nervous System:** dizziness, somnolence, insomnia, dry mouth, nervousness, abnormal dreams, tremor, depression, hypertension, paresthesia, libido decreased, agitation, anxiety, twitching. **Respiratory System:** pharyngitis, yawn, sinusitis. **Skin:** sweating. **Special Senses:** abnormal vision. **Urogenital System:** abnormal ejaculation, impotence, orgasmic dysfunction (including anorgasmia) in females. **Vital Sign Changes:** Effexor XR was associated with a mean increase in pulse rate of about 2 beats/min in depression and GAD trials and a mean increase in pulse rate of 4 beats/min in SAD trials. (See **WARNINGS: Sustained Hypertension**). **Laboratory Changes:** Clinically relevant increases in serum cholesterol were noted in Effexor XR clinical trials. Increases were duration dependent over the study period and tended to be greater with higher doses. **Other Events Observed During the Premarketing Evaluation of Effexor and Effexor XR**—N=6,670. "Frequent"=events occurring in at least 1/100 patients; "infrequent"=1/100 to 1/1000 patients; "rare"=<fewer than 1/1000 patients. **Body as a whole:** Frequent: chest pain substernal, chills, fever, neck pain; Infrequent: face edema, intentional injury, malaise, moniliasis, neck rigidity, pelvic pain, photosensitivity reaction, suicide attempt, withdrawal syndrome; Rare: appendicitis, bacteremia, carcinoma, cellulitis. **Cardiovascular system** - Frequent: migraine, postural hypotension, tachycardia; Infrequent: angina pectoris, arrhythmia, extrasystoles, hypotension, peripheral vascular disorder (mainly cold feet and/or cold hands), syncope, thrombophlebitis; Rare: aortic aneurysm, arteritis, first-degree atrioventricular block, bigeminy, bundle branch block, capillary fragility, cerebral ischemia, coronary artery disease, congestive heart failure, heart arrest, hematoxia, cardiovascular disorder (mitral valve and circulatory disturbance), mucocutaneous hemorrhage, myocardial infarct, pallor, sinus arrhythmia. **Digestive system** - Frequent: increased appetite; Infrequent: bruxism, colitis, dysphagia, tongue edema, esophagitis, gastritis, gastroenteritis, gastrointestinal ulcer, gingivitis, glossitis, rectal hemorrhage, hemorrhoids, melena, oral moniliasis, stomatitis, mouth ulceration; Rare: abdominal distension, bilary pain, cheilitis, cholecystitis, cholelithiasis, esophageal spasms, duodenitis, hematemesis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gum hemorrhage, hepatitis, ileitis, jaundice, intestinal obstruction, liver tenderness, parotitis, peritonitis, proctitis, rectal disorder, salivary gland enlargement, increased salivation, soft stools, tongue discoloration. **Endocrine system** - Rare: galactorrhea, goiter, hyperthyroidism, hypothyroidism, thyroid nodule, thyroïditis. **Hemic and lymphatic system** - Frequent: ecchymosis; Infrequent: anemia, leukocytosis, leukopenia, lymphadenopathy, thrombocytopenia; Rare: basophilic bleeding time increased, cyanosis, eosinophilia, lymphocytosis, multiple myeloma, purpura, thrombocytopenia. **Metabolic and nutritional** - Frequent: edema, weight gain; Infrequent: alkaline phosphatase increased, dehydration, hypercholesterolemia, hyperglycemia, hyperlipemia, hypoglycemia, hypokalemia, SGOT increased, thirst; Rare: alcohol intolerance, bilirubinuria, BUN increased, creatinine increased, diabetes mellitus, glycosuria, gout, healing abnormal, hemochromatosis, hypercalcinuria, hyperkalemia, hyperphosphatemia, hyperuricemia, hypcholesterolemia, hyponatremia, hypophosphatemia, hypoproteinemia, uremia. **Musculoskeletal system** - Frequent: arthralgia; Infrequent: arthritis, arthrosis, bone spurs, bursitis, leg cramps, myasthenia, tenosynovitis; Rare: bone pain, pathological fracture, muscle cramp, muscle spasms, musculoskeletal stiffness, myopathy, osteoporosis, osteosclerosis, plantar fascitis, rheumatoid arthritis, tendon rupture. **Nervous system** - Frequent: amnesia, confusion, depersonalization, hypoesthesia, thinking abnormal, trismus, vertigo; Infrequent: akathisia, apathy, ataxia, circumoral paresthesia, CNS stimulation, emotional lability, euphoria, hallucinations, hostility, hyperesthesia, hyperkinesia, hypotonia, incoordination, manic reaction, myoclonus, neuralgia, neuropathy, psychosis, seizure, abnormal speech, stupor, suicidal ideation; Rare: abnormal/changed behavior, adjustment disorder, akinesia, alcohol abuse, aphasia, bradyness, buccoglossal syndrome, cerebrovascular accident, feeling drunk, loss of consciousness, delusions, dementia, dystonia, energy increased, facial paralysis, abnormal gait, Guillain-Barré syndrome, homicidal ideation, hyperchlorhydria, hypokinesia, hysteria, impulse control difficulties, libido increased, motion sickness, neuritis, nystagmus, paranoid reaction, paresis, psychotic depression, reflexes decreased, reflexes increased, torticollis. **Respiratory system** - Frequent: cough increased, dyspnea; Infrequent: asthma, chest congestion, epistaxis, hyperventilation, laryngismus, laryngitis, pneumonia, voice alteration; Rare: atelectasis, hemoptysis, hypoxia, larynx edema, pleurisy, pulmonary embolus, sleep apnea. **Skin and appendages** - Frequent: pruritus; Infrequent: acne, alopecia, contact dermatitis, dry skin, eczema, maculopapular rash, psoriasis, urticaria; Rare: brittle nails, erythema nodosum, exfoliative dermatitis, lichenoid dermatitis, hair discoloration, skin discoloration, furunculosis, hirsutism, leukoderma, miliaria, petechial rash, pruritic rash, pustular rash, vesiculobullous rash, seborrhea, skin atrophy, skin hyperpigmentation, skin striae, sweating decreased. **Special senses** - Frequent: abnormality of accommodation, mydriasis, taste perversion; Infrequent: conjunctivitis, diplopia, dry eyes, eye pain, hyperacusis, otitis media, parosmia, photophobia, taste loss, visual field defect; Rare: blepharitis, cataract, chromatopsia, conjunctival edema, corneal lesion, deafness, exophthalmos, eye hemorrhage, glaucoma, retinal hemorrhage, subconjunctival hemorrhage, keratitis, labyrinthitis, miosis, pupilledema, decreased pupillary reflex, otitis externa, scleritis, uveitis. **Urogenital system** - Frequent: prostatic disorder (prostatitis, enlarged prostate, and prostate irritability), urination impaired; Infrequent: albuminuria, amenorrhea, cystitis, dysuria, hematuria, kidney calculus, kidney pain, leukorrhea, menorrhagia, metrorrhagia, nocturia, breast pain, polyuria, pyuria, urinary incontinence, urinary retention, urinary urgency, vaginal hemorrhage, vaginitis; Rare: abortion, anuria, balanitis, bladder pain, breast discharge, breast engorgement, breast enlargement, endometriosis, female lactation, fibrotic breast, calcium crystalluria, cervicitis, orchitis, ovarian cyst, prolonged erection, gynecomastia (male), hypomenorrhea, kidney function abnormal, mastitis, menopause, pyelonephritis, oliguria, salpingitis, uteritis, uterine hemorrhage, uterine spasms, vaginal dryness. **Postmarketing Reports:** agranulocytosis, anaphylaxis, aplastic anemia, catatonia, congenital anomalies, CPK increased, deep vein thrombophlebitis, delirium, EKG abnormalities such as QT prolongation; cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia, ventricular extrasystoles, and rare reports of ventricular fibrillation and ventricular tachycardia, including torsades de pointes; epidermal necrolysis/Stevens-Johnson syndrome, erythema multiforme, extrapyramidal symptoms (including dyskinesia and tardive dyskinesia), angle-closure glaucoma, hemorrhage (including eye and gastrointestinal bleeding), hepatic events (including GGT elevation; abnormalities of specified liver function tests; liver damage, necrosis, or failure; and fatty liver), interstitial lung disease (including pulmonary eosinophilia), involuntary movements, LDH increased, neuroleptic malignant syndrome-like events (including a case of a 10-year-old who may have been taking methylenedioxylidide, was treated and recovered), neutropenia, night sweats, pancreatitis, pancytopenia, panic, prolactin increased, renal failure, rhabdomyolysis, serotonin syndrome, shock-like electrical sensations or tinnitus (in some cases, subsequent to the discontinuation of venlafaxine or tapering of dose), and SIADH (usually in the elderly). Elevated clozapine levels that were temporally associated with adverse events, including seizures, have been reported following the addition of venlafaxine. Increases in prothrombin time, partial thromboplastin time, or INR have been reported when venlafaxine was given to patients on warfarin therapy. **DRUG ABUSE AND DEPENDENCE:** Effexor XR is not a controlled substance. Evaluate patients carefully for history of drug abuse and observe such patients closely for signs of misuse or abuse. **OVERDOSE:** Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, bradycardia, hypotension, altered level of consciousness (ranging from somnolence to coma), rhabdomyolysis, seizures, vertigo, liver necrosis, and death have been reported. Treatment should consist of those general measures employed in the management of overdosage with any antidepressant. Ensure an adequate airway, oxygenation and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for venlafaxine are known. In managing overdosage, consider the possibility of multiple drug involvement. Consider contacting a poison control center for additional information on the treatment of overdose. Telephone numbers for certified poison control centers are listed in the Physician's Desk Reference® (PDR). **DOSAGE AND ADMINISTRATION:** Consult full prescribing information for dosing instructions. **Switching Patients to or From an MAOI**—At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with Effexor XR. At least 7 days should be allowed after stopping Effexor XR before starting an MAOI (see **CONTRAINdications** and **WARNINGS**). This brief summary is based on Effexor XR Prescribing Information W10404C024, revised June 2006.

Take a closer look at Dialogues™ Time to Talk™

Dialogues

is a unique patient support and education program that is designed to help you foster successful therapy

Dialogues

offers patients access to a call center to speak with a health care provider for patient support and education to reinforce your efforts

Dialogues

supplies feedback and updates about these patient calls to you, their physician

Encourage your **EFFEXOR XR** patients to enroll in **Dialogues** by calling 866-313-3737 — and you can visit mddpatientsupport.com

- The most common adverse events reported in EFFEXOR XR short-term placebo-controlled depression, generalized anxiety disorder (GAD), social anxiety disorder (SAD), and/or panic disorder (PD) trials (incidence ≥10% and ≥2x that of placebo) were anorexia, asthenia, constipation, dizziness, dry mouth, ejaculation problems, impotence, insomnia, nausea, nervousness, somnolence, and sweating.

**ONCE-DAILY
VENLAFAXINE HCl
EFFEXOR XR® EXTENDED
RELEASE
CAPSULES**

The change they deserve.

References: 1. Data on file, Wyeth Pharmaceuticals Inc. 2. Effexor XR® (venlafaxine HCl) Extended-Release and Effexor Immediate-Release Prescribing Information, Wyeth Pharmaceuticals Inc.

Please see brief summary of Prescribing Information on adjacent pages.

Wyeth®

© 2006, Wyeth Pharmaceuticals Inc., Philadelphia, PA 19101
120493-01 July 2006

CLINICAL UPDATES IN NEUROPSYCHIATRY**908 News From the Field of Neuroscience**

- ***Patients With MDD Have Certain Brain Region Not Affected by Positive Stimuli***
- ***Increased Awareness of Dementia in Late Life May Improve Quality of Life in Elderly***
- ***Treatment of Depression Should Be Individualized to Improve Response***
- ***Alzheimer's Disease May Be Detected Through Blood Biomarkers***
- ***Brain Chemical Function Altered in Women With MDD***

LETTER TO THE EDITOR**906 Effectiveness of Lidocaine Patch 5% in Patients With or Without Allodynia****EXPERT REVIEW SUPPLEMENT****Utilization of Long-Acting Antipsychotic Medication in Patient Care**

By John M. Kane, MD

CME QUIZ**975 The quiz is CME-accredited by the Mount Sinai School of Medicine for 3.0 credit hours.**

Founded in 1996, CNS Spectrums is indexed in the Index Medicus database and is available on MEDLINE under the citation *CNS Spectr. CNS Spectrums*. *CNS Spectrums* is also distributed to all CINP members and is accredited for international CME by EACIC.

CNS Spectrums (ISSN 1092-8529) is published monthly by MBL Communications, Inc. 333 Hudson Street, 7th Floor, New York, NY 10013.

One-year subscription rates: domestic \$120; foreign \$195; in-training \$85. For subscriptions: Tel: 212-328-0800; Fax: 212-328-0600; Web: www.cns-spectrums.com. Single issues: \$15 – E-mail ks@mblcommunications.com

For editorial inquiries, please fax us at 212-328-0600 or E-mail José Ralat at jrr@mblcommunications.com. For bulk reprint purchases, please contact Christopher Naccari at cdn@mblcommunications.com.

Subscribers: send address changes to *CNS Spectrums* c/o MMS, Inc., 185 Hansen Court, Suite 110, Wood Dale, IL 60191-1150.

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., *CNS Spectrums*, LLC, or the editorial advisory board.

Advertisements in *CNS Spectrums* are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by *CNS Spectrums* or the publisher.

CNS Spectrums is a registered trademark of *CNS Spectrums*, LLC, New York, NY. Permission to reproduce articles in whole or part must be obtained in writing from the publisher.



BPA member since July 2005.

Copyright © 2006 by MBL Communications, Inc. All rights reserved. Printed in the United States.

Now approved for bipolar depression

- One treatment for BOTH bipolar depression and mania¹
- Once-a-day dosing for bipolar depression*¹

Important Safety Information

- SEROQUEL is indicated for the treatment of depressive episodes in bipolar disorder; acute manic episodes in bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex; and schizophrenia. Patients should be periodically reassessed to determine the need for treatment beyond the acute response
- Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death, compared to placebo (4.5% vs 2.6%, respectively). SEROQUEL is not approved for the treatment of patients with dementia-related psychosis (see Boxed Warning)
- Suicidality in children and adolescents—antidepressants increased the risk of suicidal thinking and behavior (4% vs 2% for placebo) in short-term studies of nine antidepressant drugs in children and adolescents with major depressive disorder and other psychiatric disorders. Patients started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL is not approved for use in pediatric patients (see Boxed Warning)
- Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia. A rare condition referred to as neuroleptic malignant syndrome has been reported with this class of medications, including SEROQUEL
- Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including SEROQUEL. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing
- Precautions include the risk of seizures, orthostatic hypotension, and cataract development
- The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials were dry mouth, somnolence, sedation, dizziness, asthenia, constipation, abdominal pain, postural hypotension, pharyngitis, weight gain, SGPT increase, dyspepsia, and lethargy

*Dosing for bipolar mania and schizophrenia is twice daily.

Please see Brief Summary of Prescribing Information,
including Boxed Warnings, on adjacent pages.

Reference: 1. SEROQUEL Prescribing Information.

SEROQUEL is a registered trademark of the AstraZeneca group of companies.

www.SEROQUEL.com

© 2006 AstraZeneca Pharmaceuticals LP. All rights reserved.



Seroquel®
quetiapine fumarate

25 mg, 50 mg, 100 mg, 200 mg, 300 mg & 400 mg tablets

Redefine Success

AstraZeneca

I always wanted to be part of a team Now I can

Proven efficacy

To help patients achieve continued success^{†1-4}

Trusted tolerability

To help patients stay on treatment¹⁻⁵

Important Safety Information

SEROQUEL is indicated for the treatment of depressive episodes in bipolar disorder; acute manic episodes in bipolar I disorder, as either monotherapy or adjunct therapy to lithium or divalproex; and schizophrenia. Patients should be periodically reassessed to determine the need for treatment beyond the acute response.

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk (1.6 to 1.7 times) of death, compared to placebo (4.5% vs 2.6%, respectively). SEROQUEL is not approved for the treatment of patients with dementia-related psychosis. (see Boxed Warning)

Suicidality in children and adolescents—antidepressants increased the risk of suicidal thinking and behavior (4% vs 2% for placebo) in short-term studies of nine antidepressant drugs in children and adolescents with major depressive disorder and other psychiatric disorders. Patients started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL is not approved for use in pediatric patients. (see Boxed Warning)

Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia. A rare condition referred to as neuroleptic malignant syndrome has been reported with this class of medications, including SEROQUEL.

Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including SEROQUEL. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.

Precautions include the risk of seizures, orthostatic hypotension, and cataract development. The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials were dry mouth, somnolence, sedation, dizziness, asthenia, constipation, abdominal pain, postural hypotension, pharyngitis, weight gain, SGPT increase, dyspepsia, and lethargy.

* All atypical prescriptions: Total prescriptions: Jan. 05-Sept. 06. New prescriptions: Sept. 04-Sept. 06. IMS Health. National Prescription Audit.

[†] Significant improvement in all 11 YMRS items was measured at Day 21 and continued through Day 84 in monotherapy mania trials.

Please see Brief Summary of Prescribing Information, including Boxed Warnings, on adjacent pages.

References: 1. Vieta E, Mullen J, Brecher M, et al. *Curr Med Res Opin.* 2005;21:923-934. 2. Sachs G, Chengappa KNR, Suppes T, et al. *Bipolar Disord.* 2004;6:213-223. 3. Small JG, Kolar MC, Kellams JJ. *Curr Med Res Opin.* 2004;20:1017-1023. 4. Kasper S, Brecher M, Fittou L, et al. *Int Clin Psychopharmacol.* 2004;19:281-289. 5. SEROQUEL Prescribing Information.

SEROQUEL is a registered trademark of the AstraZeneca group of companies.

© 2006 AstraZeneca Pharmaceuticals LP. All rights reserved.

245708

11/06

www.SEROQUEL.com

#1 prescribed atypical*

 **Seroquel®**
quetiapine fumarate

25 mg, 50 mg, 100 mg, 200 mg, 300 mg & 400 mg tablets

AstraZeneca 

SEROQUEL® (quetiapine fumarate) Tablets

BRIEF SUMMARY OF Prescribing Information—Before prescribing, please consult complete Prescribing Information.

Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of seventeen placebo-controlled trials (median duration of 10 weeks) in these patients revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10 week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. SEROQUEL (quetiapine) is not approved for the treatment of patients with Dementia-Related Psychosis.

Suicidality in Children and Adolescents: Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of SEROQUEL or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL is not approved for use in pediatric patients. [See WARNINGS and PRECAUTIONS, Pediatric Use.] Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive-compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials. [See WARNINGS and PRECAUTIONS.]

INDICATIONS AND USAGE: Bipolar Disorder: SEROQUEL is indicated for the treatment of both: • depressive episodes associated with bipolar disorder; • acute manic episodes associated with bipolar I disorder as either monotherapy or adjunct therapy to lithium or divalproex. Depression: The efficacy of SEROQUEL was established in two identical 8-week randomized, placebo-controlled double-blind clinical studies that included either bipolar I or II patients. Effectiveness has not been systematically evaluated in clinical trials for more than 8 weeks. Mania: The efficacy of SEROQUEL acute bipolar mania was established in two 12-week monotherapy trials and one 3-week adjunct therapy trial of bipolar I patients initially hospitalized for up to 7 days for acute mania. Effectiveness has not been systematically evaluated in clinical trials for more than 12 weeks in monotherapy 3 weeks in adjunct therapy. The physician who elects to use SEROQUEL for extended periods in bipolar disorder should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient. Schizophrenia: SEROQUEL is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL in schizophrenia was established in short-term (6-week) controlled trials of schizophrenic inpatients. The effectiveness of SEROQUEL in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use SEROQUEL for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

CONTRAINDICATIONS: SEROQUEL is contraindicated in individuals with a known hypersensitivity to this medication or any of its ingredients.

WARNINGS: Increased Mortality in Elderly Patient with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. SEROQUEL (quetiapine) is not approved for the treatment of patients with dementia-related psychosis (see Boxed Warning). Clinical Worsening and Suicide Risk: Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. There has been a long standing concern that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients. Antidepressants increase the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with major depressive disorder (MDD) and other psychiatric disorders. Pooled analyses of short-term placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with MDD, OCD, or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal behavior or thinking (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. There was considerable variation in risk among drugs, but a tendency toward an increase for almost all drugs studied. The risk of suicidality was most consistently observed in the MDD trials, but there were signals of risk arising from some trials in other psychiatric indications (obsessive-compulsive disorder and social anxiety disorder) as well. No suicides occurred in any of these trials. It is unknown whether the suicidality risk in pediatric patients extends to longer-term use, i.e., beyond several months. It is also unknown whether the suicidality risk extends to adults. All pediatric patients being treated with antidepressants for any indication should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Such observation would generally include at least weekly face-to-face contact with patients or their family members or caregivers during the first 4 weeks of treatment, then every other week visits for the next 4 weeks, then at 12 weeks, and as clinically indicated beyond 12 weeks. Additional contact by telephone may be appropriate between face-to-face visits. Adults with MDD or co-morbid depression in the setting of other psychiatric illness being treated with antidepressants should be observed similarly for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and non-psychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms. Families and caregivers of pediatric patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and non-psychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for SEROQUEL should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. Families and caregivers of adults being treated for depression should be similarly advised. It should be noted that SEROQUEL is not approved for use in treating any indications in the pediatric population. **Neuroleptic Malignant Syndrome (NMS):** A potentially fatal symptom complex sometimes referred to as NMS has been reported in association with administration of antipsychotic drugs, including SEROQUEL. Rare cases of NMS have been reported with SEROQUEL. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability. See full Prescribing Information for information on the management of NMS. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored since recurrences of NMS have been reported. **Tardive Dyskinesia (TD):** A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause TD is unknown. The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself; however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, SEROQUEL should be prescribed in a manner that is most likely to minimize the occurrence of TD. Chronic antipsychotic treatment should generally be reserved for patients who appear to suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically. If signs and symptoms of TD appear in a patient on SEROQUEL, drug discontinuation should be considered. However, some patients may require treatment with SEROQUEL despite the presence of the syndrome. **Hyperglycemia and Diabetes Mellitus:** Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including SEROQUEL. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse events in patients treated with atypical antipsychotics are not available. Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (eg, obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polyuria, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

PRECAUTIONS: General: Orthostatic Hypotension: SEROQUEL may induce orthostatic hypotension associated with dizziness, tachycardia, and, in some patients, syncope, especially during the initial dose titration period, probably reflecting its α_1 -adrenergic antagonist properties. Syncope was reported in 1% (28/269) of the patients treated with SEROQUEL, compared with 0.2% (2/954) on placebo and about 0.4% (5/297) on active control drugs. SEROQUEL should be used with particular caution in patients with a history of seizures or with conditions that potentially lower the seizure threshold, eg, Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in a population of 65 years or older. **Hypothyroidism:** Clinical trials with SEROQUEL demonstrated a dose-related decrease in total and free thyroxine (T4) of approximately 20% at the higher end of the therapeutic dose range and was maximal in the first two to four weeks of treatment and maintained without adaptation or progression during more chronic therapy. In nearly all cases, cessation of SEROQUEL treatment was associated with a reversal of the effects on total and free T4, irrespective of the duration of treatment. About 0.7% (26/348) of SEROQUEL patients did experience TSH increases in monotherapy studies. Six of the patients with TSH increases needed replacement thyroid treatment. In themania adjunct studies, where SEROQUEL was added to lithium or divalproex, 12% (24/196) of SEROQUEL treated patients compared to 7% (15/203) of placebo treated patients had elevated TSH levels. Of the SEROQUEL treated patients with elevated TSH levels, 3 had simultaneous low free T4 levels.

Cholesterol and Triglyceride Elevations: In schizophrenia trials, the proportions of patients with elevations to levels of cholesterol >240 mg/dL and triglycerides \geq 200 mg/dL were 16% and 23% for SEROQUEL treated patients respectively compared to 7% and 16% for placebo patients respectively. In bipolar depression trials, the proportion of patients with cholesterol and triglycerides elevations to these levels were 9% and 14% for SEROQUEL treated patients respectively, compared to 6% and 9% for placebo patients respectively. **Hypoproactinemia:** Although an elevation of prolactin levels was not demonstrated in clinical trials with SEROQUEL, increased prolactin levels were observed in rat studies with this compound, and were associated with an increase in mammary gland neoplasia in rats (see Carcinogenesis). Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent *in vitro*, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds, the clinical significance of elevated serum prolactin levels is unknown for most patients. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time. **Transaminase Elevations:** Asymptomatic, transient and reversible elevations in serum transaminases (primarily ALT) have been reported. In schizophrenia trials, the proportions of patients with transaminase elevations of \geq 3 times the upper limits of the normal reference range in a pool of 3- to 6-week placebo-controlled trials were approximately 6% for SEROQUEL compared to 1% for placebo. In acute bipolar mania trials, the proportions of patients with transaminase elevations of \geq 3 times the upper limits of the normal reference range in a pool of 3- to 12-week placebo-controlled trials were approximately 1% for both SEROQUEL and placebo. These hepatic enzyme elevations usually occurred within the first 3 weeks of drug treatment and promptly returned to pre-study levels with ongoing treatment with SEROQUEL. In bipolar depression trials, the proportions of patients with transaminase elevations of \geq 3 times the upper limits of the normal reference range in two 8-week placebo-controlled trials was 1% for SEROQUEL and 2% for placebo. **Potential for Cognitive and Motor Impairment:** Somnolence was a common reported adverse event reported in patients treated with SEROQUEL especially during the 3-5 day period of initial dose titration. In schizophrenia trials, somnolence was reported in 18% of patients on SEROQUEL compared to 11% of placebo patients. In acute bipolar mania trials using SEROQUEL as monotherapy, somnolence was reported in 16% of patients on SEROQUEL compared to 9% of placebo patients. In bipolar depression trials, somnolence was reported in 28% of patients on SEROQUEL compared to 7% of placebo patients. In these trials, sedation was reported in 30% of patients on SEROQUEL compared to 8% of placebo patients. Since SEROQUEL has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that SEROQUEL therapy does not affect them adversely. **Prismism:** One case of prismism in a patient receiving SEROQUEL has been reported prior to market introduction. While a causal relationship to use of SEROQUEL has not been established, other drugs with alpha-adrenergic blocking effects have been reported to induce prismism, and it is possible that SEROQUEL may share that capacity. Severe prismism may require surgical intervention. **Body Temperature Regulation:** Although not reported with SEROQUEL, disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing SEROQUEL for patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. **Dysphagia:** Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. SEROQUEL and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

Suicide: The possibility of a suicide attempt is higher in bipolar disorder and schizophrenia; close supervision of high risk patients should accompany drug therapy. Prescriptions for SEROQUEL should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of overdose. In 2-week clinical studies in patients with bipolar depression (N=1048) the incidence of treatment emergent suicidal ideation or suicide attempt was low and similar to placebo (SEROQUEL 300 mg, 6/350, 1.7%; SEROQUEL 600 mg 9/348, 2.6%; Placebo, 7/347, 2.0%). **Use in Patients with Concomitant Illness:** Clinical experience with SEROQUEL in patients with certain concomitant systemic illnesses is limited. SEROQUEL has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical studies. Because of the risk of orthostatic hypotension with SEROQUEL, caution should be observed in cardiac patients (see Orthostatic Hypotension). **Information for Patients:** Physicians are advised to consult the full Prescribing Information for details of the following issues to discuss with patients for whom they prescribe SEROQUEL. **Orthostatic Hypotension, Interference with Cognitive and Motor Performance, Pregnancy, Nursing, Concomitant Medication, Alcohol, and Heat Exposure and Dehydration, Laboratory Tests:** No specific laboratory tests are recommended. **Drug Interactions:** The risks of using SEROQUEL in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of SEROQUEL, caution should be used when it is taken in combination with other centrally acting drugs. SEROQUEL potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotropic disorders, and alcoholic beverages should be avoided while taking SEROQUEL. Because of its potential for inducing hypertension, SEROQUEL may enhance the effects of certain antihypertensive agents. SEROQUEL may antagonize the effects of levodopa and dopamine agonists. **The Effect of Other Drugs on Quetiapine:** Coadministration of quetiapine (250 mg tid) and phenytoin (100 mg tid) increased the mean oral clearance of quetiapine by 5-fold. Increased doses of SEROQUEL may be required to maintain control of symptoms of schizophrenia in patients receiving quetiapine and phenytoin, or other hepatic enzyme inducers (e.g., carbamazepine, barbiturates, rifampin, glucocorticoids). Caution should be taken if phenytoin is withdrawn and replaced with a non-inducer (e.g., valproate). **Divalproex:** Coadministration of quetiapine (150 mg bid) and divalproex (500 mg bid) increased the mean maximum plasma concentration of quetiapine at steady state by 17% without affecting the extent of absorption or mean oral clearance. **Thioridazine:** Thioridazine (200 mg bid) increased the oral clearance of quetiapine (300 mg bid) by 65%. **Cimetidine:** Administration of multiple daily doses of cimetidine (400 mg bid for 4 days) resulted in a 20% decrease in the mean oral clearance of quetiapine (150 mg tid). Dose adjustment for quetiapine is not required when it is given with cimetidine. **P450 3A4 Inhibitors:** Coadministration of ketocazole (200 mg once daily for 4 days), a potent inhibitor of cytochrome P450 3A4, reduced oral clearance of quetiapine by 84%, resulting in a 335% increase in maximum plasma concentration of quetiapine. Caution is indicated when SEROQUEL is administered with ketoconazole and other inhibitors of cytochrome P450 3A4 (e.g., itraconazole, fluconazole, and erythromycin). **Fluoxetine, Imipramine, Haloperidol, and Risperidone:** Coadministration of fluoxetine (60 mg once daily), imipramine (75 mg bid), haloperidol (1.75 mg bid), and risperidone (3 mg bid) with quetiapine (300 mg bid) did not alter the steady-state pharmacokinetics of quetiapine. **Effect of Quetiapine on Other Drugs:** **Lorazepam:** The mean oral clearance of lorazepam (2 mg single dose) was reduced by 20% in the presence of quetiapine administered as 250 mg tid dosing. **Divalproex:** The mean maximum concentration and extent of absorption of total and free valproic acid at steady state were decreased by 10 to 12% when divalproex (500 mg bid) was administered with quetiapine (150 mg bid). The mean oral clearance of total valproic acid (administered as divalproex 500 mg bid) was increased by 11% in the presence of quetiapine (150 mg bid). The changes were not significant. **Lithium:** Concomitant administration of quetiapine (250 mg tid) with lithium had no effect on any of the steady-state pharmacokinetic parameters of lithium. **Antipyrine:** Coadministration of antipyrine (60 mg once daily), imipramine (75 mg bid), haloperidol (1.75 mg bid), and risperidone (3 mg bid) with quetiapine (300 mg bid) did not alter the steady-state pharmacokinetics of quetiapine. **Effect of Quetiapine on Other Drugs:** Lorazepam. The mean oral clearance of lorazepam (2 mg single dose) was reduced by 20% in the presence of quetiapine administered as 250 mg tid dosing. **Divalproex:** The mean maximum concentration and extent of absorption of total and free valproic acid at steady state were decreased by 10 to 12% when divalproex (500 mg bid) was administered with quetiapine (150 mg bid). The mean oral clearance of total valproic acid (administered as divalproex 500 mg bid) was increased by 11% in the presence of quetiapine (150 mg bid). The changes were not significant. **Lithium:** Concomitant administration of quetiapine (250 mg tid) with lithium had no effect on any of the steady-state pharmacokinetic parameters of lithium. **Antipyrine:** Administration of multiple daily doses up to 750 mg/day (on a tid schedule) of quetiapine to subjects with selected psychiatric disorders had no clinically relevant effect on the clearance of antipyrine or urinary recovery of antipyrine metabolites. These results indicate that quetiapine does not significantly induce hepatic enzymes responsible for cytochrome P450 mediated metabolism of antipyrine. **Carcinogenesis, Mutagenesis, Impairment of Fertility:** Carcinogenicity studies were conducted in C57BL mice and Wistar rats. There were statistically significant increases in thyroid gland follicular adenomas in male mice at doses of 250 and 750 mg/kg or 3.0 times the maximum human dose on a mg/m² basis and in male rats at a dose of 250 mg/kg or 3.0 times the maximum human dose on a mg/m² basis. Mammary gland adenocarcinomas were statistically significantly increased in female rats at all doses tested (25, 75, and 250 mg/kg or 0.3, 0.9, and 3.0 times the maximum recommended human dose on a mg/m² basis). Thyroid follicular cell adenomas may have resulted from chronic stimulation of the thyroid by thyroid stimulating hormone (TSH) resulting from enhanced metabolism and clearance of thyroxine by rodent liver. Changes in TSH, thyroxine, and thyroxine clearance consistent with this mechanism were observed in subchronic toxicity studies in rat and mouse and in a 1-year toxicity study in rat; however, the results of these studies were not definitive. The relevance of the increases in thyroid follicular cell adenomas to human risk, through whatever mechanism, is unknown. Serum measurements in a 1-year toxicity study showed that quetiapine increased median serum prolactin levels a maximum of 32- and 13-fold in male and female rats, respectively. Increases in mammary neoplasms have been found in rodents after chronic administration of other antipsychotic drugs and are considered to be prolactin-mediated. The relevance of this increased incidence of prolactin-mediated mammary gland tumors in rats to human risk is unknown (see Hyperprolactinemia in PRECAUTIONS, General). **Mutagenesis:** The mutagenic potential of quetiapine was tested in six *In vitro* bacterial gene mutation assays and in an *In vitro* mammalian genome mutation assay in Chinese Hamster Ovary cells. However, sufficiently high concentrations of quetiapine may not have been used for all test strains. Quetiapine did produce a reproducibly increase in mutations in one *Salmonella typhimurium* tester strain in the presence of metabolic activation. No evidence of clastogenic potential was obtained in an *In vitro* chromosomal aberration assay in cultured human lymphocytes or in the *In vitro* micronucleus assay in rats. **Impairment of Fertility:** Quetiapine decreased mating and fertility in male Sprague-Dawley rats at oral doses of 50 and 150 mg/kg or 0.6 and 1.8 times the maximum human dose on a mg/m² basis. Drug-related effects included increases in interval to mate and in the number of matings required for successful impregnation. These effects continued to be observed at 150 mg/kg even after a two-week period without treatment. The no-effect dose for impaired mating and fertility in male rats was 25 mg/kg, or 0.3 times the maximum human dose on a mg/m² basis. Quetiapine adversely affected mating and fertility in female Sprague-Dawley rats at an oral dose of 50 mg/kg, or 0.6 times the maximum human dose on a mg/m² basis. Drug-related effects included decreases in matings and in matings resulting in pregnancy, and an increase in the interval to mate. An increase in irregular estrus cycles was observed at doses of 10 and 50 mg/kg, or 0.1 and 0.6 times the maximum human dose on a mg/m² basis. The no-effect dose in female rats was 1 mg/kg, or 0.01 times the maximum human dose on a mg/m² basis. There was an increased incidence of a minor soft tissue anomaly (carpal/arsal flexure) in rabbit fetuses at a dose of 100 mg/kg (2.4 times the maximum human dose on a mg/m² basis). Evidence of maternal toxicity (i.e., decrease in body weight gain and/or death) was observed at the high dose in the rat study and at all doses in the rabbit study. In a per/postnatal reproductive study in rats, no drug-related effects were observed at doses of 10, 0.1, and 0.02 times the maximum human dose on a mg/m² basis. However, in a preliminary per/postnatal study, there were increases in fetal weight and pup death, and decreases in mean litter weight at 150 mg/kg, or 3.0 times the maximum human dose on a mg/m² basis. There are no adequate and well-controlled studies in pregnant women and quetiapine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Labor and Delivery:** The effect of SEROQUEL on labor and delivery in humans is unknown. **Nursing Mothers:** SEROQUEL was excreted in milk of treated animals during lactation. It is not known if SEROQUEL is excreted in human milk. It is recommended that women receiving SEROQUEL should not breast feed. **Pediatric Use:** The safety and effectiveness of SEROQUEL in pediatric patients have not been established. Anyone considering the use of SEROQUEL in a child or adolescent must balance the potential risks with the clinical need. **Geriatric Use:** Of the approximately 3700 patients in clinical studies with SEROQUEL, 7% (232) were 65 years of age or older. Nevertheless, the presence of factors that might decrease pharmacokinetic clearance, increase the pharmacodynamic response to SEROQUEL, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period in the elderly. The mean plasma clearance of SEROQUEL was reduced by 30% to 50% in elderly patients when compared to younger patients.

ADVERSE REACTIONS: The information below is derived from a clinical trial database for SEROQUEL consisting of over 3700 patients. Of these approximately 3700 subjects, approximately 3400 (2300 in schizophrenia, 405 in acute bipolar mania, and 595 in bipolar depression) were patients who participated in multiple dose effectiveness trials, and their experience corresponded to approximately 992.5 patient-years. Refer to the full Prescribing Information for details of adverse event data collection. **Adverse Findings Observed in Short-Term, Controlled Trials: Adverse Events Associated with Discontinuation in Treatment in Short-Term, Placebo-Controlled Trials:** **Bipolar Disorder:** Depression: Overall, discontinuations due to adverse events were 12.3% for SEROQUEL 300 mg vs 19.0% for SEROQUEL 600 mg and 5.2% for placebo. Mania: Overall, discontinuations due to adverse events were 5.7% for SEROQUEL vs 5.1% for placebo in monotherapy and 3.6% for SEROQUEL vs 5.9% for placebo in adjunct therapy. **Schizophrenia:** Overall, there was little difference in the incidence of discontinuation due to adverse events (4% for SEROQUEL vs 3% for placebo) in a pool of controlled trials. However, discontinuations due to somnolence (0.8% vs 0.5% for placebo) and hypotension (0.4% vs 0.4% for placebo) were considered to be drug related (see PRECAUTIONS, Adverse Events Occurring at an Incidence of 1% or More Among SEROQUEL Treated Patients in Short-Term, Placebo-Controlled Trials): The following treatment-emergent

continued

SEROQUEL® (quetiapine fumarate) Tablets

BRIEF SUMMARY of Prescribing Information (continued)—Before prescribing, please consult complete Prescribing Information.

adverse events occurred during acute therapy of schizophrenia (up to 6 weeks) and bipolar mania (up to 12 weeks) in 1% or more of patients treated with SEROQUEL (doses ranging from 75 to 800 mg/day) where the incidence in patients treated with SEROQUEL was greater than the incidence in placebo-treated patients. **Treatment-Emergent Adverse Experience Incidence in 3- to 12-Week Placebo-Controlled Clinical Trials* for the Treatment of Schizophrenia and Bipolar Mania (monotherapy): Body as a Whole:** Headache, Pain, Asthenia, Abdominal, Back Pain, Fever, Cardiovascular, Tachycardia, Postural Hypotension, **Digestive:** Dry Mouth, Constipation, Vomiting, Dyspepsia, Gastroenteritis, Gamma-Glutamyl Transpeptidase Increased, **Metabolic:** Weight Gain, SGPT increased, SGOT increased, **Nervous:** Agitation, Somnolence, Dizziness, Anxiety, **Respiratory:** Pharyngitis, Rhinitis, Skin Appendages, Rash, **Special Senses:** Amblyopia. In these studies, the most commonly observed adverse events associated with the use of SEROQUEL (incidence of 5% or greater) and observed at a rate on SEROQUEL at least twice that of placebo were somnolence (18%), dizziness (11%), dry mouth (9%), constipation (8%), SGPT increased (5%), weight gain (5%), and dyspepsia (5%). (*Events for which the SEROQUEL incidence was equal to or less than placebo are not listed in the table, but included the following: accidental injury, akathisia, chest pain, cough increased, depression, diarrhea, extrapyramidal syndrome, hostility, hypertension, hypertonia, hypotension, increased appetite, infection, insomnia, leukopenia, malaise, nausea, nervousness, paresis, peripheral edema, sweating, tremor, and weight loss.) Table 2, from the full Prescribing Information, enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred during therapy (up to 3 weeks) of acute mania in 5% or more of patients treated with SEROQUEL (doses ranging from 100 to 800 mg/day) used as adjunct therapy to lithium and divalproex where the incidence in patients treated with SEROQUEL was greater than the incidence in placebo-treated patients. **Treatment-Emergent Adverse Experience Incidence in 3-Week Placebo-Controlled Clinical Trials† for the Treatment of Bipolar Mania (Adjunct Therapy): Body as a Whole:** Headache, Asthenia, Abdominal Pain, Back Pain, **Cardiovascular:** Postural Hypotension; **Digestive:** Dry Mouth, Constipation; **Metabolic and Nutritional:** Weight Gain, **Nervous:** Somnolence, Dizziness, Tremor, Agitation; **Respiratory:** Pharyngitis. In these studies, the most commonly observed adverse events associated with the use of SEROQUEL (incidence of 5% or greater) and observed at a rate on SEROQUEL at least twice that of placebo were somnolence (34%), dry mouth (19%), asthenia (10%), constipation (10%), abdominal pain (7%), postural hypotension (7%), pharyngitis (6%), and weight gain (6%). (*Events for which the SEROQUEL incidence was equal to or less than placebo are not listed in the table, but included the following: akathisia, diarrhea, insomnia, and nausea.) Table 3, in the full Prescribing Information, enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred during therapy (up to 8 weeks) of bipolar depression in 5% or more of patients treated with SEROQUEL (doses of 300 and 600 mg/day) where the incidence in patients treated with SEROQUEL was greater than the incidence in placebo-treated patients. **Treatment-Emergent Adverse Experience Incidence in 8-Week Placebo-Controlled Clinical Trials for the Treatment of Bipolar Depression: Gastrointestinal Disorders:** Dry Mouth, Constipation, Dyspepsia, Vomiting; **General Disorders and Administrative Site Conditions:** Fatigue, Metabolism and Nutrition Disorders: Increased Appetite; **Nervous System Disorders:** Sedation, Somnolence, Dizziness, Lethargy, **Respiratory, Thoracic, and Mediastinal Disorders:** Nasal Congestion. In these studies, the most commonly observed adverse events associated with the use of SEROQUEL (incidence of 5% or greater) and observed at a rate on SEROQUEL at least twice that of placebo were dry mouth (44%), sedation (30%), somnolence (28%), dizziness (18%), constipation (10%), lethargy (5%), and nasal congestion (5%). (*Events for which the SEROQUEL incidence was equal to or less than placebo are not listed in the table, but included the following: nausea, upper respiratory tract infection, and headache.) Explorations for interactions on the basis of gender, age, and race did not reveal any clinically meaningful differences in the adverse event occurrence on the basis of these demographic factors. **Dose Dependency of Adverse Events in Short-Term, Placebo-Controlled Trials: Dose-related Adverse Events:** Logistic regression analyses revealed a positive dose response ($p<0.05$) for the following adverse events: dyspepsia, abdominal pain, and weight gain. **Extrapyramidal Symptoms:** Data from one 6-week clinical trial of schizophrenia comparing five fixed doses of SEROQUEL (75, 150, 300, 600, 750 mg/day) provided evidence for the lack of treatment-emergent extrapyramidal symptoms (EPS) and dose-relatedness for EPS associated with SEROQUEL treatment. Three methods were used to measure EPS: (1) Simpson-Angus total score (mean change from baseline) which evaluates parkinsonism and akathisia, (2) incidence of spontaneous complaints of EPS (akathisia, akinesia, cogwheel rigidity, extrapyramidal syndrome, hypertonia, hypokinesia, neck rigidity, and tremor), and (3) use of anticholinergic medications to treat emergent EPS. In six additional placebo-controlled clinical trials (3 in acute mania and 3 in schizophrenia) using variable doses of SEROQUEL, there were no differences between the SEROQUEL and placebo treatment groups in the incidence of EPS, as assessed by Simpson-Angus total scores, spontaneous complaints of EPS and the use of concomitant anticholinergic medications to treat EPS. In two placebo-controlled clinical trials for the treatment of bipolar depression using 300 mg and 600 mg of SEROQUEL, the incidence of adverse events related to EPS was 12% in both dose groups and 6% in the placebo group. In these studies, the incidence of the individual adverse events (eg, akathisia, extrapyramidal disorder, tremor, dyskinesia, dystonia, restlessness, muscle contractions involuntary, psychomotor hyperactivity and muscle rigidity) were generally low and did not exceed 4% in any treatment group. The 3 treatment groups were similar in mean change in SAS total score and BARS Global Assessment score at the end of treatment. The use of concomitant anticholinergic medications was infrequent and similar across the three treatment groups. **Vital Signs and Laboratory Studies: Vital Sign Changes:** SEROQUEL is associated with orthostatic hypotension (see PRECAUTIONS). **Weight Gain:** In schizophrenia trials the proportions of patients meeting a weight gain criterion of $\geq 7\%$ of body weight were compared in a pool of four 3- to 6-week placebo-controlled clinical trials, revealing a statistically significantly greater incidence of weight gain for SEROQUEL (23%) compared to placebo (6%). In mania monotherapy trials the proportions of patients meeting the same weight gain criterion were 21% compared to 7% for placebo and in mania adjunct therapy trials the proportion of patients meeting the same weight criterion were 13% compared to 4% for placebo. In bipolar depression trials, the proportions of patients meeting the same weight gain criterion were 8% compared to 2% for placebo. **Laboratory Changes:** An assessment of the premarketing experience for SEROQUEL suggested that it is associated with asymptomatic increases in SGPT and increases in both total cholesterol and triglycerides (see PRECAUTIONS). **ECG Changes:** Between group comparisons for pooled placebo-controlled trials revealed no statistically significant SEROQUEL/placebo differences in the proportions of patients experiencing potentially important changes in ECG parameters, including QT, QTc, and PR intervals. However, the proportions of patients meeting the criteria for tachycardia were compared in four 3- to 6-week placebo-controlled clinical trials for the treatment of schizophrenia revealing a 1% (4/399) incidence for SEROQUEL compared to 0.8% (1/156) incidence for placebo. In acute (monotherapy) bipolar mania trials the proportions of patients meeting the criteria for tachycardia was 0.5% (1/192) for SEROQUEL compared to 0% (0/178) incidence for placebo. In acute bipolar mania (adjunct) trials the proportions of patients meeting the same criteria was 0.8% (1/166) for SEROQUEL compared to 0% (0/71) incidence for placebo. In bipolar depression trials, no patients had heart rate increases to > 120 beats per minute. SEROQUEL use was associated with a mean increase in heart rate, assessed by ECG, of 7 beats per minute compared to a mean increase of 1 beat per minute among placebo patients. This slight tendency to tachycardia may be related to SEROQUEL's potential for inducing orthostatic changes (see PRECAUTIONS). **Other Adverse Events Observed During the Pre-Marketing Evaluation of SEROQUEL:** Events are categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); infrequent adverse events are those occurring in 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. **Nervous System:** **Frequent:** hypertonia, dysarthria; **Infrequent:** abnormal dreams, dyskinesia, thinking abnormal, tardive dyskinesia, vertigo, involuntary movements, confusion, amnesia, psychosis, hallucinations, hyperkinetic, libido increased*, urinary retention, incoordination, paranoid reaction, abnormal gait, myoclonus, delusions, manic reaction, apathy, ataxia, depersonalization, stupor, bruxism, catatonic reaction, hemiplegia; **Rare:** aphasia, buccoglossal syndrome, choreoathetosis, delirium, emotional lability, euphoria, libido decreased*, neuralgia, stuttering, subdural hematoma. **Body as a Whole:** **Frequent:** flu syndrome, **Infrequent:** neck pain, pelvic pain*, suicide attempt, malaise, photosensitivity reaction, chills, face edema, miosis; **Rare:** abdomen enlarged. **Digestive System:** **Frequent:** anorexia; **Infrequent:** increased salivation, increased appetite, gamma-glutamyl transpeptidase increased, pruritus, dysphagia, flatulence, gastritis, gastritis, hemorrhoids, stomatitis, thirst, tooth caries, fecal incontinence, gastroesophageal reflux, gum hemorrhage, mouth ulceration, rectal hemorrhage, tongue edema; **Rare:** glossitis, hematemesis, intestinal obstruction, melena, cyanosis. **Cardiovascular System:** **Frequent:** palpitation; **Infrequent:** vasodilatation, QT interval prolonged, migraine, bradycardia, cerebral ischemia, irregular pulse, T wave abnormality, bundle branch block, cerebrovascular accident, deep thrombophlebitis, T wave inversion; **Rare:** angina pectoris, atrial fibrillation, AV block first degree, congestive heart failure, ST elevated, thrombophlebitis, T wave flattening, ST abnormality, increased QRS duration. **Respiratory System:** **Frequent:** pharyngitis, rhinitis, cough increased, dyspnea; **Infrequent:** pneumonia, epistaxis, asthma; **Rare:** hiccup, hyperventilation. **Metabolic and Nutritional System:** **Frequent:** peripheral edema; **Infrequent:** weight loss, alkaline phosphatase increased, hyperlipemia, alcohol intolerance, dehydration, hyperglycemia, creatinine increased, hypoglycemia; **Rare:** glycosuria, gout, hand edema, hypokalemia, water intoxication. **Skin and Appendages System:** **Frequent:** sweating; **Infrequent:** pruritus, acne, eczema contact dermatitis, maculopapular rash, seborrhea, skin ulcer; **Rare:** exfoliative dermatitis, psoriasis, skin discoloration. **Urogenital System:** **Infrequent:** dysmenorrhea*, vaginitis*, urinary incontinence, metrorrhagia*, impotence*, dysuria, vaginal moniliasis*, abnormal ejaculation*, cystitis, urinary frequency, amenorrhea*, female lactation*, leukorrhea*, vaginal hemorrhage*, vulvovaginitis*, orchitis*; (*adjusted for gender); **Rare:** gynecomastia*, nocturia, polyuria, acute kidney failure. **Special Senses:** **Infrequent:** conjunctivitis, abnormal vision, dry eyes, tinnitus, taste perversion, blepharitis, eye pain; **Rare:** abnormality of accommodation, deafness, glaucoma. **Musculoskeletal System:** **Infrequent:** pathological fracture, myasthenia, twitching, arthralgia, arthritis, leg cramps, bone pain. **Hemic and Lymphatic System:** **Frequent:** leukopenia; **Infrequent:** leukocytosis, anemia, ecchymosis, eosinophilia, hypochromic anemia; lymphadenopathy, cyanosis; **Rare:** hemolytic, thrombocytopenia. **Endocrine System:** **Infrequent:** hypothyroidism, diabetes mellitus; **Rare:** hypothyroidism. **Poss Marketing Experience:** Adverse events reported since market introduction which were temporally related to SEROQUEL therapy include: leukopenia/neutropenia. If a patient develops a low white cell count and history of drug induced leukopenia/neutropenia. Other adverse events reported since market introduction, which were temporally related to SEROQUEL therapy, but not necessarily causally related, include the following: agranulocytosis, anaphylaxis, hyponatremia, rhabdomyolysis, syndrome of inappropriate antidiuretic hormone secretion (SIADH), and Steven Johnson syndrome (SJS).

DRUG ABUSE AND DEPENDENCE: **Controlled Substance Class:** SEROQUEL is not a controlled substance. **Physical and Psychologic Dependence:** SEROQUEL has not been systematically studied in animals or humans, for its potential for abuse, tolerance or physical dependence. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of misuse or abuse of SEROQUEL, e.g., development of tolerance, increases in dose, drug-seeking behavior.

OVERDOSAGE: **Human experience:** Experience with SEROQUEL in acute overdose was limited in the clinical trial database (6 reports) with estimated doses ranging from 1200 mg to 9600 mg and no fatalities. In general, reported signs and symptoms were those resulting from an exaggeration of the drug's known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension. One case, involving an estimated overdose of 9600 mg, was associated with hypokalemia and first degree heart block. In post-marketing experience, there have been very rare reports of overdose of SEROQUEL alone resulting in death, coma, or OTC prolongation. **Management of Overdose:** In case of acute overdose, establish and maintain an airway and ensure adequate oxygenation and ventilation. Gastric lavage (after intubation, if patient is unconscious) and administration of activated charcoal together with a laxative should be considered. The possibility of obtundation, seizure or dys tonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis. **Cardiovascular monitoring** should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with acute overdose of SEROQUEL. Similarity it is reasonable to expect that the alpha-adrenergic-blocking properties of bretylium might be additive to those of quetiapine, resulting in problematic hypotension. There is no specific antidote to SEROQUEL. Therefore appropriate supportive measures should be instituted. The possibility of multiple drug involvement should be considered. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of quetiapine-induced alpha blockade). In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers.

SEROQUEL® is a trademark of the AstraZeneca group of companies

©AstraZeneca 2006. AstraZeneca Pharmaceuticals LP, Wilmington, DE 19805 Made in USA

30417-00 Rev. 10/06

244363

CNS Spectrums
is proud to
announce...

A NEW CLINICAL COLUMN

"Trends in Psychopharmacology"

by
Stephen M.
Stahl, MD, PhD

February
2007